Industry sponsor intelligence
Lead-sponsor view of Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
Pipeline overview
Velocity
Study start year · indexed snapshot
Development
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Liraglutide → | 1 | 0 | 0 | 0 | 1 | 1 |
| Mazdutide → | 1 | 0 | 0 | 1 | 0 | 1 |
| Dulaglutide → | 1 | 0 | 1 | 0 | 0 | 1 |
Active peptide trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes
Phase 3
Not yet recruiting
912
2026-02
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · T2DM (Type 2 Diabetes Mellitus)
Phase 4
Recruiting
430
2025-11
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes
Phase 2
Recruiting
216
2025-08
Completed trials
Search sponsor records
This page groups studies where Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
3 matching studies
Last registry update first
Recent updates